Purified exosomal product triggers wound healing in preclinical model
Ischemic wounds in preclinical models have been healed using an acellular product developed by the Mayo Clinic (MN, USA), with normal scar-free skin after treatment. Published in the journal Theranostics, the team documented restoration of skin integrity, hair follicles, sweat glands, skin oils and normal hydration, laying the foundation for clinical studies to test the safety of using the purified exosomal product (PEP) for would healing in patients.
Chronic ischemic wounds are common among individuals with conditions such as diabetes, pressure ulcers, hardening of arteries, traumatic injury or side effects of radiation therapy. While the current standard treatments of wound dressing, topical gels and surgery offer some relief, they often cannot fully close the wound. Consequently, approximately 7 million people in the USA experience non-healing wounds.
In this study, the researchers at Mayo examined the effects of the purified exosomal product, derived from platelets and comprising extracellular vesicles that target damaged tissue, on animal models in which wounds with low blood supply had been replicated.
“We found that this exosome therapy has the ability to enhance regeneration of blood vessels in damaged tissues. Without treatment, chronic ischemic wounds grow larger and more problematic,” explained Ao Shi, a student in the Regenerative Sciences Training Program in Mayo Clinic Graduate School of Biomedical Sciences and first author.
The product is manufactured under strict quality control measures and formulated as a dry powder to enable long-term storage at room temperature. When in use, the powder is mixed with a hydrogel solution on-site and can be applied directly to the wound.
Steven Moran, a Mayo Clinic plastic surgeon and senior co-author of the study, noted that wounds were healed with only a single application of the exosome. “I was surprised that this product regenerated healthy skin with normal biomechanical properties – not scar tissue. As this technology is now scaled and biomanufactured for clinical applications, it creates the potential for huge advancement in medical science and the field of plastic surgery.”
“What we see with this technology is not just that the wound is closed, but also that the blood supply to the tissue is restored. Our effort culminating in the development of this exosomal technology was to create a therapy that can be offered to all patients in need through elimination of logistical limitations often seen with more traditional regenerative therapy,” commented Atta Behfar, Deputy Director of Translation, Mayo Clinic’s Center for Regenerative Medicine and senior author.
The study has opened up the opportunity for US FDA approval to begin a first-in-class clinical trial to test the safety of using this product for the healing of ischemic wounds in patients.
Behfar continues: “Our research hopes to answer whether this can be a new healing solution for patients suffering with nonhealing chronic wounds.”
Link: https://www.regmednet.com/purified-exosomal-product-triggers-wound-healing-in-preclinical-model/
ارسال به دوستان